In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BlueRock Therapeutics launches with $225mm Series A round from Bayer, Versant

Executive Summary

Regenerative medicine start-up BlueRock Therapeutics (induced pluripotent stem cell (iPSC) therapies) was launched with a $225mm Series A investment from Bayer AG (through Leaps by Bayer) and Versant Ventures.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies